<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">ateroskleroz</journal-id><journal-title-group><journal-title xml:lang="ru">Атеросклероз</journal-title><trans-title-group xml:lang="en"><trans-title>Ateroscleroz</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2078-256X</issn><issn pub-type="epub">2949-3633</issn><publisher><publisher-name>НИИТПМ-филиал ИЦиГ СО РАН</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.52727/2078-256X-2021-17-2-51-60</article-id><article-id custom-type="elpub" pub-id-type="custom">ateroskleroz-436</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНЫЕ СТАТЬИ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>ORIGINAL ARTICLES</subject></subj-group></article-categories><title-group><article-title>Лептин и кардиометаболические факторы риска у лиц с избыточной массой тела в молодом возрасте</article-title><trans-title-group xml:lang="en"><trans-title>Leptin and cardiometabolic risk factors in overweight persons in young age</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-4716-876X</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Мустафина</surname><given-names>С. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Mustafina</surname><given-names>S. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p> д-р мед. наук, старший научный сотрудник лаборатории клинико-популяционных и профилактических исследований терапевтических и эндокринных заболеваний</p><p>630089, Новосибирск, ул. Бориса Богаткова, 175/1</p></bio><bio xml:lang="en"><p> 630089, Novosibirsk, Boris Bogatkov str., 175/1 </p></bio><email xlink:type="simple">svetlana3548@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-2470-2133</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Денисова</surname><given-names>Д. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Denisova</surname><given-names>D. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p> д-р мед. наук, главный научный сотрудник лаборатории профилактической медицины</p><p>630089, Новосибирск, ул. Бориса Богаткова, 175/1</p></bio><bio xml:lang="en"><p> 630089, Novosibirsk, Boris Bogatkov str., 175/1 </p></bio><email xlink:type="simple">denisovadiana@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-1645-5523</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Алфёрова</surname><given-names>В. И.</given-names></name><name name-style="western" xml:lang="en"><surname>Alferova</surname><given-names>V. I.</given-names></name></name-alternatives><bio xml:lang="ru"><p> младший научный сотрудник лаборатории генетических и средовых детерминант жизненного цикла человека</p><p>630089, Новосибирск, ул. Бориса Богаткова, 175/1</p></bio><bio xml:lang="en"><p> 630089, Novosibirsk, Boris Bogatkov str., 175/1 </p></bio><email xlink:type="simple">lady.alfyorova2009@yandex.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-0436-2549</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Шрамко</surname><given-names>В. С.</given-names></name><name name-style="western" xml:lang="en"><surname>Shramko</surname><given-names>V. S.</given-names></name></name-alternatives><bio xml:lang="ru"><p> канд. мед. наук, научный сотрудник лаборатории клинических биохимических и гормональных исследований терапевтических заболеваний </p><p>630089, Новосибирск, ул. Бориса Богаткова, 175/1</p></bio><bio xml:lang="en"><p> 630089, Novosibirsk, Boris Bogatkov str., 175/1 </p></bio><email xlink:type="simple">Shramko-90@inbox.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-9270-9188</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Щербакова</surname><given-names>Л. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Shcherbakova</surname><given-names>L. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p> старший научный сотрудник лаборатории клинико-популяционных и профилактических исследований терапевтических и эндокринных заболеваний</p><p>630089, Новосибирск, ул. Бориса Богаткова, 175/1</p></bio><bio xml:lang="en"><p> 630089, Novosibirsk, Boris Bogatkov str., 175/1 </p></bio><email xlink:type="simple">9584792@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru">НИИ терапии и профилактической медицины – филиал ФГБНУ ФИЦ Институт цитологии и генетики СО РАН<country>Россия</country></aff><aff xml:lang="en">Research Institute of Internal and Preventive Medicine – Branch of Federal Research Center Institute of Cytology and Genetics of SB RAS<country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2021</year></pub-date><pub-date pub-type="epub"><day>10</day><month>08</month><year>2021</year></pub-date><volume>17</volume><issue>2</issue><fpage>51</fpage><lpage>60</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Мустафина С.В., Денисова Д.В., Алфёрова В.И., Шрамко В.С., Щербакова Л.В., 2021</copyright-statement><copyright-year>2021</copyright-year><copyright-holder xml:lang="ru">Мустафина С.В., Денисова Д.В., Алфёрова В.И., Шрамко В.С., Щербакова Л.В.</copyright-holder><copyright-holder xml:lang="en">Mustafina S.V., Denisova D.V., Alferova V.I., Shramko V.S., Shcherbakova L.V.</copyright-holder><license license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://ateroskleroz.elpub.ru/jour/article/view/436">https://ateroskleroz.elpub.ru/jour/article/view/436</self-uri><abstract><sec><title> Цель исследования</title><p> Цель исследования: изучить ассоциации уровня лептина с кардиометаболическими факторами риска у лиц молодого возраста с избыточной массой тела. </p></sec><sec><title>Материал и методы</title><p>Материал и методы. Из репрезентативной выборки молодого населения Октябрьского района г. Новосибирска в возрасте 25–35 лет (636 человек) выделены лица с  избыточной (196 человек) и нормальной массой тела (197 человек, группа контроля), в сыворотке крови которых определяли содержание лептина (393 человека). Дизайн исследования – «случай – контроль». Избыточная масса тела определялась при индексе массы тела (ИМТ) ≥ 25 кг/м2. Уровень лептина измеряли методом иммунофлуоресцентного анализа с помощью тест-систем Elisa (Diagnostics Biochem Canada Inc., Canada) на анализаторе Multiskan EX (Thermo Fisher Scientific, Финляндия). Для расчетов использовались медиана и интерквартильный размах (Me [25; 75]). </p></sec><sec><title>Результаты</title><p>Результаты. Концентрация лептина в группе лиц с ИМТ ≥ 25 кг/м2 была в 4 раза больше, чем в группе контроля (17,0[8,6; 36,9] и 4,4 [1,5; 13,1] нг/мл соответственно). Проанализированы показатели факторов риска в квартилях лептина: выявлено, что у мужчин и женщин, вошедших в Q4 по содержанию лептина, были больше, чем у вошедших в Q1, окружность талии, окружность бедер, ИМТ, артериальное давление, концентрация триглицеридов; также у них отмечено увеличение частоты метаболического синдрома и снижение уровня холестерина липопротеинов высокой плотности. Кроме того, у мужчин, в отличие от женщин, в Q4 лептина выявлено возрастание концентрации общего холестерина и холестерина липопротеинов низкой плотности. По данным ROC-анализа с высоким уровнем лептина крови ассоциированы все изученные антропометрические параметры, отражающие избыточный вес, а максимальные ассоциации установлены между ожирением II степени (ИМТ более 35 кг/м2) и нормальной массой тела – площадь под ROC-кривой 0,91, р &lt; 0,001. Пороговое значение содержания лептина для выявления метаболического синдрома у мужчин составляет 6,5 нг/мл, у женщин – 25,8 нг/мл.</p></sec><sec><title>Заключение</title><p>Заключение. Уровень лептина в сыворотке крови ассоциирован с кардиометаболическими факторами риска и метаболическим синдромом, а концентрация лептина более 6,5 нг/мл у мужчин и 25,8 нг/мл у женщин характерна для лиц с метаболическим синдромом. </p></sec></abstract><trans-abstract xml:lang="en"><p> Aim of the study was to investigate the associations of leptin levels with cardiometabolic risk factors in overweight young people. </p><sec><title>Material and methods</title><p>Material and methods. From a representative sample of the young population of the Oktyabrsky district of Novosibirsk at the age of 25–35  years (636 people), all overweight people (196 persons) and people with normal body weight (control group 197 persons) were chosen for determination of serum leptin (393 people). Study design – case-control. Overweight was determined according to body mass index (BMI) ≥ 25 kg/m2. Leptin levels were determined by immunofluorescence analysis (IFA) using Elisa test systems (Diagnostics Biochem Canada Inc., Canada) on an IFA analyzer Multiscan EX (Finland). For calculations, the median and  interquartile range were used (Me [25; 75]). </p></sec><sec><title>Results</title><p>Results. Leptin level in the study group with BMI ≥ 25 kg/m2 was 4 times higher than in the control group (17.0 [8.6; 36.9] and 4.4 [1.5; 13,1] ng/ml, respectively). The indicators of risk factors in leptin content quartiles were analyzed: it was found that in men and women included in leptin Q4the waist circumference, hip circumference, BMI, blood pressure, triglyceride content were more than in Q1; they also showed an increase in the frequency of metabolic syndrome and a decrease in the level of high-density cholesterol. In addition, in men, in contrast to women, leptin Q4 showed an increase in total cholesterol and low-density cholesterol level. According to the ROC analysis, all studied anthropometric parameters reflecting overweight were associated with a high level of blood leptin, and the maximum associations were found between obesity grade II (BMI more than 35 kg/m2) and normal body weight – area under ROC curve 0.91, p &lt; 0.001. The threshold value of the leptin level for detecting MS in men is 6.5 ng/ml, in women 25.8 ng/ml.</p></sec><sec><title>Conclusions</title><p>Conclusions. Serum leptin levels are associated with cardiometabolic risk factors and metabolic syndrome in young population, and leptin levels above 6.5 ng/ml in men and 25.8 ng/ml in women are characteristic of individuals with metabolic syndrome. </p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>избыточная масса тела</kwd><kwd>ожирение</kwd><kwd>лептин</kwd><kwd>кардиометаболические факторы риска</kwd><kwd>молодая популяция</kwd></kwd-group><kwd-group xml:lang="en"><kwd>overweight</kwd><kwd>obesity</kwd><kwd>leptin</kwd><kwd>cardiometabolic risk factors</kwd><kwd>young population</kwd></kwd-group><funding-group xml:lang="ru"><funding-statement>Работа выполнена в рамках бюджетной темы по Государственному заданию АААА-А17-117112850280-2 и при финансовой поддержке гранта РФФИ 19-013-00800 «Многолетняя динамика избыточной массы тела среди молодых россиян: оценка вклада генетических, поведенческих и социально-экономических факторов в рост распространенности ожирения в России».</funding-statement></funding-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Eckle R.H., Grundy S.M., Zimmet P.Z. The metabolism syndrome. Lancet, 2005; 365 (9468): 1415–1428.</mixed-citation><mixed-citation xml:lang="en">Eckle R.H., Grundy S.M., Zimmet P.Z. The metabolism syndrome. Lancet, 2005; 365 (9468): 1415–1428.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Симонова Г.И., Мустафина С.В., Печенкина Е.А. Распространенность метаболического синдрома в Сибири: популяционное исследование в г. Новосибирске. Бюл. СО РАМН, 2011; 31 (5): 100–106.</mixed-citation><mixed-citation xml:lang="en">Симонова Г.И., Мустафина С.В., Печенкина Е.А. Распространенность метаболического синдрома в Сибири: популяционное исследование в г. Новосибирске. Бюл. СО РАМН, 2011; 31 (5): 100–106.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Galassi A., Reynolds K., He J. Metabolic syndrome and risk of cardiovascular disease: a meta-analysis. Am. J. Med., 2006; 119 (10): 812–819.</mixed-citation><mixed-citation xml:lang="en">Galassi A., Reynolds K., He J. Metabolic syndrome and risk of cardiovascular disease: a meta-analysis. Am. J. Med., 2006; 119 (10): 812–819.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Mustafina S.V., Rymar O.D., Shcherbakova L.V. et al. The risk of type 2 diabetes mellitus in a Russian population cohort according to data from the HAPIEE project. J. Personal. Med., 2021; 11 (2): 1–15.</mixed-citation><mixed-citation xml:lang="en">Mustafina S.V., Rymar O.D., Shcherbakova L.V. et al. The risk of type 2 diabetes mellitus in a Russian population cohort according to data from the HAPIEE project. J. Personal. Med., 2021; 11 (2): 1–15.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Huang K.C., Lin R.C., Kormas N. et al: Plasma leptin is associated with insulin resistance independent of age, body mass index, fat mass, lipids, and pubertal development in nondiabetic adolescents. Int. J. Obes. Relat. Metab. Disord., 2004; 28 (4): 470–475.</mixed-citation><mixed-citation xml:lang="en">Huang K.C., Lin R.C., Kormas N. et al: Plasma leptin is associated with insulin resistance independent of age, body mass index, fat mass, lipids, and pubertal development in nondiabetic adolescents. Int. J. Obes. Relat. Metab. Disord., 2004; 28 (4): 470–475.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Hodge A.M., Boyko E.J., de Courten M. et al: Leptin and other components of the metabolic syndrome in Mauritius – a factor analysis. Int. J. Obes. Relat. Metab. Disord., 2001; 25 (1): 126–131.</mixed-citation><mixed-citation xml:lang="en">Hodge A.M., Boyko E.J., de Courten M. et al: Leptin and other components of the metabolic syndrome in Mauritius – a factor analysis. Int. J. Obes. Relat. Metab. Disord., 2001; 25 (1): 126–131.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Дедов И.И., Мельниченко Г.А., Бутрова С.А. Жировая ткань как эндокринный орган. Ожирение и метаболизм, 2006; 3 (1): 6–13. doi: 10.14341/2071-8713-49375</mixed-citation><mixed-citation xml:lang="en">Дедов И.И., Мельниченко Г.А., Бутрова С.А. Жировая ткань как эндокринный орган. Ожирение и метаболизм, 2006; 3 (1): 6–13. doi: 10.14341/2071-8713-49375</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Jung C.H., Kim M.-S. Molecular mechanisms of central leptin resistance in obesity. Arch. Pharm. Res., 2013; 36: 201–207. doi: 10.1007/s12272-013-0020-y</mixed-citation><mixed-citation xml:lang="en">Jung C.H., Kim M.-S. Molecular mechanisms of central leptin resistance in obesity. Arch. Pharm. Res., 2013; 36: 201–207. doi: 10.1007/s12272-013-0020-y</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Vu J.P., Larauche M., Flores M. et al. Regulation of appetite, body composition, and metabolic hormones by vasoactive intestinal polypeptide (VIP). J. Mol. Neurosci., 2015; 56: 377–387. doi: 10.1007/s12031-015-0556-z</mixed-citation><mixed-citation xml:lang="en">Vu J.P., Larauche M., Flores M. et al. Regulation of appetite, body composition, and metabolic hormones by vasoactive intestinal polypeptide (VIP). J. Mol. Neurosci., 2015; 56: 377–387. doi: 10.1007/s12031-015-0556-z</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Friedman J.M. Leptin, leptin receptors, and the control of body weight. Nutr. Rev., 1998; 56: S38–S46. doi: 10.1111/j.1753-4887.1998.tb01685.x</mixed-citation><mixed-citation xml:lang="en">Friedman J.M. Leptin, leptin receptors, and the control of body weight. Nutr. Rev., 1998; 56: S38–S46. doi: 10.1111/j.1753-4887.1998.tb01685.x</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Najam S.S., Awan F.R., Islam M. et al. Leptin correlation with obesity, diabetes and gender in a population from Faisalabad, Pakistan. Arch. Med., 2016, 8: 5. doi: 10.21767/1989-5216.1000169</mixed-citation><mixed-citation xml:lang="en">Najam S.S., Awan F.R., Islam M. et al. Leptin correlation with obesity, diabetes and gender in a population from Faisalabad, Pakistan. Arch. Med., 2016, 8: 5. doi: 10.21767/1989-5216.1000169</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Kazmi A., Tariq K.M., Hashim R. Association of leptin with type diabetes in non-obese subjects. J. Ayub. Med. Coll. Abbottabad, 2012; 24: 186–189.</mixed-citation><mixed-citation xml:lang="en">Kazmi A., Tariq K.M., Hashim R. Association of leptin with type diabetes in non-obese subjects. J. Ayub. Med. Coll. Abbottabad, 2012; 24: 186–189.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Awede B., Adovoekpe D., Adehan G. et al. Adiponectin, in contrast to leptin, is not associated with body mass index, waist circumference and HOMA-IR in subjects of a West-African population. Physiol. Rep., 2018; 6: e13718–e13724, doi: 10.14814/phy2.13718</mixed-citation><mixed-citation xml:lang="en">Awede B., Adovoekpe D., Adehan G. et al. Adiponectin, in contrast to leptin, is not associated with body mass index, waist circumference and HOMA-IR in subjects of a West-African population. Physiol. Rep., 2018; 6: e13718–e13724, doi: 10.14814/phy2.13718</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Kumari R., Kumar S., Kant R. An update on metabolic syndrome: Metabolic risk markers and adipokines in the development of metabolic syndrome. Diabetes Metab. Syndr., 2019; 13: 2409–2417. doi: 10.1016/j.dsx.2019.06.005</mixed-citation><mixed-citation xml:lang="en">Kumari R., Kumar S., Kant R. An update on metabolic syndrome: Metabolic risk markers and adipokines in the development of metabolic syndrome. Diabetes Metab. Syndr., 2019; 13: 2409–2417. doi: 10.1016/j.dsx.2019.06.005</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Marita A.R., Sarkar J.A., Rane S. Type diabetes in non-obese Indian subjects is associated with reduced leptin levels: study from Mumbai, Western India. Mol. Cell. Biochem., 2005; 275: 143–151.</mixed-citation><mixed-citation xml:lang="en">Marita A.R., Sarkar J.A., Rane S. Type diabetes in non-obese Indian subjects is associated with reduced leptin levels: study from Mumbai, Western India. Mol. Cell. Biochem., 2005; 275: 143–151.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Wang Z., Zhuo Q., Fu P. et al. Are the associations of plasma leptin and adiponectin with type diabetes independent of obesity in older Chinese adults? Diabetes Metab. Res. Rev., 2010; 26: 109–114.</mixed-citation><mixed-citation xml:lang="en">Wang Z., Zhuo Q., Fu P. et al. Are the associations of plasma leptin and adiponectin with type diabetes independent of obesity in older Chinese adults? Diabetes Metab. Res. Rev., 2010; 26: 109–114.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Buyukbese M.A., Cetinkaya A., Kocabas R. et al. Leptin levels in obese women with and without type diabetes mellitus. Mediators Inflamm., 2004; 13: 321–325.</mixed-citation><mixed-citation xml:lang="en">Buyukbese M.A., Cetinkaya A., Kocabas R. et al. Leptin levels in obese women with and without type diabetes mellitus. Mediators Inflamm., 2004; 13: 321–325.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Coimbra S., Brandao Proenca J., Santos-Silva A., Neuparth M.J. Adiponectin, leptin, and chemerin in elderly patients with type diabetes mellitus: a close linkage with obesity and length of the disease. Biomed. Res. Int., 2014; 2014: 701915.</mixed-citation><mixed-citation xml:lang="en">Coimbra S., Brandao Proenca J., Santos-Silva A., Neuparth M.J. Adiponectin, leptin, and chemerin in elderly patients with type diabetes mellitus: a close linkage with obesity and length of the disease. Biomed. Res. Int., 2014; 2014: 701915.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Huang K.C., Lin R.C., Kormas N. et al. Plasma leptin is associated with insulin resistance independent of age, body mass index, fat mass, lipids, and pubertal development in nondiabetic adolescents. Int. J. Obes. Relat. Metab. Disord., 2004; 28 (4): 470–475.</mixed-citation><mixed-citation xml:lang="en">Huang K.C., Lin R.C., Kormas N. et al. Plasma leptin is associated with insulin resistance independent of age, body mass index, fat mass, lipids, and pubertal development in nondiabetic adolescents. Int. J. Obes. Relat. Metab. Disord., 2004; 28 (4): 470–475.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Hamnvik O.P., Liu X., Petrou M. et al. Soluble leptin receptor and leptin are associated with baseline adiposity and metabolic risk factors, and predict adiposity, metabolic syndrome, and glucose levels at 2-year follow-up: the Cyprus Metabolism Prospective Cohort Study. Metabolism, 2011; 60 (7): 987–993, doi: 10.1016/j.metabol.2010.09.009</mixed-citation><mixed-citation xml:lang="en">Hamnvik O.P., Liu X., Petrou M. et al. Soluble leptin receptor and leptin are associated with baseline adiposity and metabolic risk factors, and predict adiposity, metabolic syndrome, and glucose levels at 2-year follow-up: the Cyprus Metabolism Prospective Cohort Study. Metabolism, 2011; 60 (7): 987–993, doi: 10.1016/j.metabol.2010.09.009</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Ingelsson E., Larson M.G., Yin X. et al: Circulating ghrelin, leptin, and soluble leptin receptor concentrations and cardiometabolic risk factors in a community-based sample. J. Clin. Endocrinol. Metab., 2008, 93 (8): 3149–3157.</mixed-citation><mixed-citation xml:lang="en">Ingelsson E., Larson M.G., Yin X. et al: Circulating ghrelin, leptin, and soluble leptin receptor concentrations and cardiometabolic risk factors in a community-based sample. J. Clin. Endocrinol. Metab., 2008, 93 (8): 3149–3157.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Yun J.E., Kimm H., Jo J., Jee S.H. Serum leptin is associated with metabolic syndrome in obese and nonobese Korean populations. Metabolism, 2010, 59 (3): 424–429.</mixed-citation><mixed-citation xml:lang="en">Yun J.E., Kimm H., Jo J., Jee S.H. Serum leptin is associated with metabolic syndrome in obese and nonobese Korean populations. Metabolism, 2010, 59 (3): 424–429.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Galletti F., Barbato A., Versiero M. et al. Circulating leptin levels predict the development of metabolic syndrome in middle-aged men: an 8-year follow-up study. J. Hypertens., 2007, 25 (8): 1671–1677.</mixed-citation><mixed-citation xml:lang="en">Galletti F., Barbato A., Versiero M. et al. Circulating leptin levels predict the development of metabolic syndrome in middle-aged men: an 8-year follow-up study. J. Hypertens., 2007, 25 (8): 1671–1677.</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Franks P.W., Brage S., Luan J. et al. Leptin predicts a worsening of the features of the metabolic syndrome independently of obesity. Obes. Res., 2005, 13 (8): 1476–1484.</mixed-citation><mixed-citation xml:lang="en">Franks P.W., Brage S., Luan J. et al. Leptin predicts a worsening of the features of the metabolic syndrome independently of obesity. Obes. Res., 2005, 13 (8): 1476–1484.</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Ghaedian M.M., Nazari Jaz A., Momeni M. et al. Plasma leptin level is positively associated with blood pressure measures independent of gender and BMI. Clin. Exp. Hypertens., 2020; 42: 31–35, doi: 10.1080/10641963.2018.1557684</mixed-citation><mixed-citation xml:lang="en">Ghaedian M.M., Nazari Jaz A., Momeni M. et al. Plasma leptin level is positively associated with blood pressure measures independent of gender and BMI. Clin. Exp. Hypertens., 2020; 42: 31–35, doi: 10.1080/10641963.2018.1557684</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Lisko I., Tiainen K., Stenholm S. et al. Are body mass index, waist circumference and waist-to-hip ratio associated with leptin in 90-year-old people? Eur. J. Clin. Nutr., 2013; 67: 420–422, doi: 10.1038/ejcn.2013.39</mixed-citation><mixed-citation xml:lang="en">Lisko I., Tiainen K., Stenholm S. et al. Are body mass index, waist circumference and waist-to-hip ratio associated with leptin in 90-year-old people? Eur. J. Clin. Nutr., 2013; 67: 420–422, doi: 10.1038/ejcn.2013.39</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
